ArticleCancers2023
Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Survival Outcomes in Hepatocellular Carcinoma: Experience from a Multidisciplinary Committee in Ecuador.Life (Basel, Switzerland) · 2025Article
- Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma.Oncology letters · 2025Article
- Automated Literature Screening for Hepatocellular Carcinoma Treatment Through Integration of 3 Large Language Models: Methodological Study.JMIR medical informatics · 2025Article
- Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.Frontiers in immunology · 2025Article
- Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.Frontiers in immunology · 2025Article
- Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2025Article
- Liver resection and transplantation in the era of checkpoint inhibitors.JHEP reports : innovation in hepatology · 2024Review
- Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response.Current oncology (Toronto, Ont.) · 2024Article
- Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma.Journal of liver cancer · 2024Article
- Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts.Cancers · 2024Review
- Resection post-radio-embolization in patients with single large hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective multicenter study analyzed 244 patients with unresectable hepatocellular carcinoma treated with lenvatinib (LEN) and atezolizumab + bevacizumab (Atezo + Bev) to examine the characteristics, treatment courses, and prognoses. The cases of patients who could achieve HCC downstaging from Barcelona Clinic Liver Cancer (BCLC) stage B or C to A or zero indicated the need for conversion therapy. The patients' prognoses with and without conversion therapy were compared. Of the 244 patients, 12 (4.9%) underwent conversion therapy, six out of 131 (4.6%) were treated with LEN, and six out of 113 (5.3%) were treated with Atezo + Bev. Eleven patients (91.7%) with a modified albumin bilirubin (mALBI) grade 1 or 2a and BCLC-B stage showed significantly higher rates of transition during conversion therapy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.